A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.
treatment period
No
Michel Marty, MD
Principal Investigator
Centre for Therapeutic Innovations in Oncology and Haematology / Saint Louis University Hospital
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
EFC10073
NCT00485979
June 2007
August 2010
Name | Location |
---|